Navigation Links
Strategic Diagnostics Inc. Selected as Key Supplier to SAIC-F and the National Cancer Institute for the Development of a Comprehensive Portfolio of Antibodies for Use in Cancer Research
Date:4/3/2008

Long Term Development Agreement to Produce Reference Standard Reagents to

Advance Cancer Research

NEWARK, Del., April 3, 2008 /PRNewswire-FirstCall/ -- Strategic Diagnostics Inc. (Nasdaq: SDIX) -- a leader in providing advanced antibody products and services to the life sciences industry announced that it has been selected by Science Applications International Corporation - Frederick (SAIC-F), to develop monoclonal antibodies for the Proteomics Reagents & Resources component of the National Cancer Institute (NCI) Clinical Proteomic Technologies for Cancer initiative (CPTC). The goal of CPTC is to accelerate discovery and clinical research in cancer using an integrated approach that assesses and optimizes proteomic technology measurement capabilities and develops universally accepted metrics that identify and minimize experimental variability from run to run, instrument to instrument, and lab to lab. CPTC aims to achieve this through the optimization of existing platforms; developing innovative proteomic technologies and computational tools; and developing community reagents and resources. The Proteomic Reagents & Resources component will include SOPs, data, proteins, and well-characterized, high-quality antibodies whose performance characteristics will be conducted at an Antibody Characterization Laboratory at NCI-Frederick (NCI-F) that is part of NCI-F's Advanced Technology Program.

SDI was awarded the competitive contract to produce monoclonal antibodies that will serve as reference reagents for the scientific cancer community based on its technical strength, large-scale capacity, standardized processes, and fully integrated quality management system.

Matthew H. Knight, SDI's President and Chief Executive Officer, commented, "SDI is very proud to have been selected to become a key supplier in this large scale initiative. This award is another example of how our commitment to efficiency, quality, capacity, and expertise has positioned us as a premier supplier of comprehensive antibody services to the research community. Being selected to supply these critical tools to advance cancer research is further validation of the exceptional team and infrastructure SDI has developed. As the study of proteins increases in importance to the research community, we foresee a continued and sustained need for SDI's expertise in antibodies as they continue to be the most widely used tools for understanding the molecular dynamics underlying disease."

Under the contract, SDI will produce monoclonal antibodies for the Clinical Proteomic Technologies for Cancer Initiative of the NCI (http://proteomics.cancer.gov) and SAIC-F and the NCI will extensively characterize these reagents consistent with their mission to make available high quality reagents with baseline data.

About Strategic Diagnostics Inc.

Strategic Diagnostics Inc. (SDI) is an antibody technology company; developing, commercializing and marketing innovative and proprietary biotechnology solutions that preserve and enhance the quality of human health. SDI's antibody division supplies critical reagents used in the diagnosis of disease. The Company's new Genomic Antibody Technology(R) is gaining wide adoption in producing custom research reagents for applied proteomic research, and drug/biomarker discovery among academic, biotech and large pharmaceutical customers. The Company's SEQer(R) antibody catalog is the fastest growing collection of polyclonal antibodies for cancer research. SDI scientists are experts in the development of immunoassays and are using the Company's capacity for high throughput production of high quality antibodies to deliver content for a new generation of multiplex assays for use in biomarker discovery. For more information, visit the Company's website at http://www.sdix.com.

This news release contains forward-looking statements reflecting SDI's current expectations. When used in this press release, the words "anticipate", "could", "enable", "estimate", "intend", "expect", "believe", "potential", "will", "should", "project", "plan" and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission.

Company Contact: Investor Contact:

Stan Fronczkowski Hayden Communications

Chief Financial Officer Brett Maas (brett@haydenir.com)

(302) 456-6789 (646) 536-7331

http://www.sdix.com


'/>"/>
SOURCE Strategic Diagnostics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities
2. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
3. Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug
4. RxElite Filling Critical Requirement for Strategic Partners in Asia, Europe, and Australia
5. Medline and 3M Agree to Strategic Partnership in Electrosurgery
6. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
7. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
8. Siemens and National Jewish Medical and Research Center Form Strategic Alliance to Advance Shared Vision of Personalized Medicine
9. Immtech Appoints Blythe Weigh as Strategic Advisor
10. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
11. Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Germany and GERMANTOWN, Maryland ... ; Frankfurt Prime Standard: QIA) today announced the introduction ... for gene expression profiling, expanding QIAGEN,s portfolio of Sample ... enable researchers to select from over 20,000 human genes ... interactions between genes, cellular phenotypes and disease processes. ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... to delivering cutting-edge information focused on the development and manufacture of biopharmaceuticals ... a premier sponsor of the 2016 BioProcess International Awards – Recognizing Excellence ...
(Date:2/11/2016)... ... February 11, 2016 , ... Reichert Technologies, ... continues today to pursue the highest level of accuracy and quality with the ... Refractometer and the AR5 Refractometer. Accurate, reliable and tough enough for the ...
(Date:2/10/2016)... WASHINGTON , February 10, 2016 Early-career ... , Peru , Uganda ... their life-enhancing work in health and nutrition   Indonesia ... Uganda and Yemen are ... sciences and epidemiology. They are also celebrated for mentoring young women scientists ...
Breaking Biology Technology:
(Date:2/2/2016)... Feb. 2, 2016   Parabon NanoLabs ... U.S. Army Research Office and the Defense Forensics ... sensitivity of the company,s Snapshot Kinship Inference ... and, more generally, defense-related DNA forensics.  Although Snapshot ... (predicting appearance and ancestry from DNA evidence), it ...
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first day ... announced plans to develop a first of its kind ... of IBM Watson. In the first application of ... (NYSE: IBM ), and Welltok will create a ... assessments with cognitive analytics, delivered on Welltok,s health optimization ...
(Date:1/27/2016)... , Jan. 27, 2016  Rite Track, Inc. ... in West Chester, Ohio announced ... winning service staff, based in Austin, Texas ... and ability to provide modifications, installations and technical support ... , CEO of PLUS, commented, "PLUS has provided world ...
Breaking Biology News(10 mins):